Endeavor BioMedicines Announces Appointment of Chris Krueger, J.D., as Chief Operating Officer

SAN DIEGO--(BUSINESS WIRE)--Endeavor BioMedicines (“Endeavor”), a clinical-stage biotechnology company developing medicines with the potential to deliver transformational clinical benefits to patients with life-threatening diseases, today announced the appointment of Chris Krueger, J.D., as Chief Operating Officer (COO). Mr. Krueger brings extensive experience from the life sciences industry that will be instrumental to Endeavor's continued growth and success.

“Chris is an extremely accomplished life sciences executive with a deep understanding of the corporate operations, development and strategy needs of a company like Endeavor BioMedicines,” said John Hood, Ph.D., Co-founder, CEO and Chairman, Endeavor BioMedicines. “We know that he will be yet another exceptional addition to our leadership team and will help us ensure operational excellence as we continue to advance our clinical programs."

Mr. Krueger has nearly 25 years of experience in the life science industry with operational responsibility and leadership for multiple functional areas, including business and corporate development, legal affairs and intellectual property, accounting and finance, human resources, alliance management and operations. He has negotiated a broad range of equity and debt financings, strategic partnerships, mergers and acquisitions and licensing transactions. Mr. Krueger’s extensive industry experience includes serving as a founder and executive officer at Ventyx Biosciences, Oppilan Pharma, Zomagen Biosciences, Escalier Biosciences, Vimalan Biosciences and Akarna Therapeutics (acquired by Allergan). Previously, he also served as an executive officer at Ardea Biosciences (acquired by AstraZeneca), Xencor, X-Ceptor Therapeutics (acquired by Exelixis) and Aurora Biosciences (acquired by Vertex Pharmaceuticals). Earlier in his career, he was a corporate lawyer at Cooley LLP representing emerging technology companies, bringing an additional depth of insight to the team.

“I’m very impressed with Endeavor BioMedicines, including their extraordinary leadership team, groundbreaking science and pipeline of prospective medicines,” said Mr. Krueger. “I’m thrilled to be joining the company at such a pivotal time and look forward to being part of the team as they strive to bring new therapies to patients who need them.”

About Endeavor BioMedicines

Endeavor BioMedicines is a clinical-stage biotechnology company developing medicines with the potential to deliver transformational clinical benefits to patients with life-threatening diseases. Endeavor’s lead candidate, ENV-101, is an inhibitor of the Hedgehog (Hh) signaling pathway in clinical development for the treatment of idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF). Their second candidate, ENV-501, is a HER3 antibody-drug conjugate (ADC) for the treatment of HER3-positive solid tumors. More information is available at www.endeavorbiomedicines.com and on LinkedIn or X.